ACA
ALNY icon

Atlas Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Atlas Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-165
Closed -$24.1K – 916
2022
Q2 		$24.1K Hold
165
– – ﹤0.01% 656
2022
Q1 		$26.9K Hold
165
– – ﹤0.01% 605
2021
Q4 		$28K Hold
165
– – ﹤0.01% 601
2021
Q3 		$31.2K Hold
165
– – 0.01% 586
2021
Q2 		$28K Hold
165
– – ﹤0.01% 609
2021
Q1 		$23.3K Buy
+165
New +$24.8K ﹤0.01% 579

Other funds holding ALNY

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Atlas Capital Advisors's ALNY Position: Q3 2022 in Review

Atlas Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 165 shares — an estimated $24.1K sold.

Atlas Capital Advisors first reported a position in ALNY in Q1 2021 and held it in 6 quarters. The position peaked at $31.2K in Q3 2021. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • Atlas Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Atlas Capital Advisors sold 165 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $24.1K.
  • Atlas Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • Atlas Capital Advisors's Alnylam Pharmaceuticals position peaked at $31.2K in Q3 2021.
  • 497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Atlas Capital Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.